Research information only, not medical advice. Animal evidence only. Not approved anywhere. Up for an FDA advisory committee vote on July 23, 2026. Banned for athletes (WADA S0) since 2022.
BPC-157 at a glance
Large rodent corpus (tendon, muscle, gut, wound healing), mostly from one group (Sikiric et al.). No published randomized controlled trial in humans as of June 2026; the entire human base is three small uncontrolled pilots plus one recruiting Phase 2 trial.
All seven peptides on the agenda are covered in the July 2026 FDA peptide meeting. See also BPC-157 vs TB-500.
Evidence profile
89 studies- Human trial 2 · 2%
- Review 42 · 47%
- Animal 29 · 33%
- In-vitro 10 · 11%
- Unknown 6 · 7%
The longer the green, the stronger the human evidence. For most research peptides the bar is dominated by animal and in-vitro work, which is a signal to read every claim carefully.
Regulatory status
- 2022-01-01 WADA
Added to the Prohibited List, class S0 — banned at all times. source
- 2023-09-29 US-FDA
Placed in 503A interim Category 2 ("significant safety risks"). source
- 2026-04-22 US-FDA
Removed from Category 2 (nominations withdrawn) — but still NOT eligible for compounding. source
- 2026-07-23 US-FDA · upcoming
FDA Pharmacy Compounding Advisory Committee votes on BPC-157, evaluated indication: ulcerative colitis (docket FDA-2025-N-6895). source
Clinical trials
-
PCO-02 - Safety and Pharmacokinetics Trial
-
BPC 157 for Acute Hamstring Muscle Strain Repair
Indexed research
Sorted by evidence level, strongest first.
- Human trial 2025Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
This pilot study in two healthy adults found that intravenous infusion of up to 20 mg of BPC-157 was safe and well-tolerated with no adverse effects.
- Human trial 2025Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.
This pilot study with two participants found that intravenous infusion of up to 20 mg of BPC-157 was safe and well-tolerated, with no adverse effects on biomarkers or reported side effects.
- Review 2026BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers
- Review 2026Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
- Review 2026Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
- Review 2026Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
- Review 2026Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation
- Review 2026From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management
- Review 2026Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis: The Role of BPC 157 and Related Therapeutics
- Review 2026Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A Review
+ 79 more studies indexed for BPC-157.
Voices
- Andrew Huberman · Huberman Lab · exploratory
- Peter Attia · The Drive · skeptical-on-this-molecule
- Sara Szal, MD · Substack · nuanced
Frequently asked questions
- Is BPC-157 approved for human use?
- Animal evidence only. Not approved anywhere. Up for an FDA advisory committee vote on July 23, 2026. Banned for athletes (WADA S0) since 2022.
- What does the research on BPC-157 show?
- Large rodent corpus (tendon, muscle, gut, wound healing), mostly from one group (Sikiric et al.). No published randomized controlled trial in humans as of June 2026; the entire human base is three small uncontrolled pilots plus one recruiting Phase 2 trial.